On track to report data from Phase 1 clinical trial evaluating VG-3927 for the treatment of Alzheimer’s disease in 1Q 2025 –– Final analysis ...
In recent years, companies and business executives increasingly are turning to neuroscience methods to better understand their customers, hire better, build effective teams and make better decisions.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback